The present disclosure provides polymers comprising at least one repeat unit represented by any one of structural formulas (IA)-(IE) disclosed herein, for example: ##STR00001##
Values for the variables are as disclosed herein. The polymers provided can be employed as ion conductors, for example in fuel cells, and have improved thermal characteristics.

Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for a variety of applications, including, but not limited to, drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention provides for dry spray compositions comprising co-polymers comprising a core, water-soluble polymer and a peptide.

A random copolymer compound of (A) a polyphenylene ether resin having phenolic hydroxy groups at both ends, (B) an aliphatic polymer having alcoholic hydroxy groups at both ends, and (C) an acid dichloride compound that is a binder is disclosed, wherein the number of mol a of the (A) polyphenylene ether resin, the number of mol b of the (B) aliphatic polymer, and the number of mol c of the (C) acid dichloride compound that is a binder satisfies the relationship (a+b)>c.

The invention contemplates certain polyethers, polyether derivatives, and methods of making and using those same polymers. For example, the starting materials can, e.g., citronellol, prenol, isocitronellol and isoprenol.

This invention provides the use of a polymer comprising a hyperbranched polyether polyol such as hyperbranched polyglycerol as a serum albumin substitute. Also provided are high molecular weight hyperbranched polyglycerol polymers suitable for a variety of medical and non-medical uses including methods for making such high molecular weight polymers.

The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds.

The present invention relates to the use of at least one tetra functional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.

A method of producing a polyether polyol includes reacting a low molecular weight initiator with one or more monomers in the presence of a polymerization catalyst, and the low molecular weight initiator has a nominal hydroxyl functionality of at least 2. The one or more monomers includes at least one selected from propylene oxide and butylene oxide. The polymerization catalyst is a Lewis acid catalyst having the general formula M(R.sup.1)1(R.sup.2)1(R.sup.3)1(R.sup.4)0 or 1, whereas M is boron, aluminum, indium, bismuth or erbium, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are each independent, R.sup.1 includes a fluoroalkyl-substituted phenyl group, R.sup.2 incudes a fluoroalkyl-substituted phenyl group or a fluoro/chloro-substituted phenyl group, R.sup.3 includes a fluoroalkyl-substituted phenyl group or a fluoro/chloro-substituted phenyl group, and optional R.sup.4 includes a functional group or functional polymer group, R.sup.1 being different from at least one of R.sup.2 and R.sup.3.

A modification of natural or synthetic polysaccharides by grafting polyetheramines, and the use of modified polysaccharides in the form of a hydrogel as a medium for cell culture. These hydrogel preparations may have heat-sensitive rheological properties that are interesting for their intracorporeal use in human and veterinary medicine, for cell culture and transport of biological samples.